The pharmaceutical industry is doubling down on its campaign to force Colombia to alter its policies toward pricing and patents for medicines by enlisting the support of a congressional ally.

Over the past month, industry groups urged U.S. trade officials to place Colombia on a list of countries that purportedly fail to enforce intellectual property rights. Trade officials responded by warning Colombia that changes are needed prior to an upcoming meeting to discuss membership in the Organization for Economic Cooperation and Development, an intergovernmental trade group.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy